Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (8245)	9/17/2000 4:36:52 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 9719

I'm a bit surprised that DGEN is 1/3 the market value of LEXG The lawsuit filed by LEXG versus DGEN, maybe? I am not familiar with the details at all, and, actually I am surprised that the DGEN IPO went through at all. Sign of our bullish times, I suppose. I still remember CEGE's (ABGX's parent) patent lawsuit that effectively killed GenPharm in the early 90's. As it is well known, and documented by Rick Harmon a few times, GenPharm had the goods all along, but now has to be happy being part of MEDX. I guess some people made out OK after all. Some links: "LEXG reiterates Patent Infringement Claims Against Deltagen" biz.yahoo.com And, in bed with the masters of this game -g-: "Abgenix and Lexicon Genetics Form Alliance for Antibody Drug Discovery ..." biz.yahoo.com PB